Portola announces positive Phase II results of andexanet alfa with Xarelto

9 January 2015
portola-big

USA-based Portola Pharmaceuticals (Nasdaq: PTLA) has announced positive results from the first part of Phase III trial of adexanet alfa withg German pharma major Bayer's (BAYN: DE) Factor Xa inhibitor Xarelto (rivaroxaban).

The study met its primary endpoint, and showed that andexanet alfa administered as an intravenous bolus significantly and immediately reversed the steady-state anticoagulation activity of Xarelto and was well-tolerated.

Portola is developing andexanet alfa, a US Food and Drug Administration-designated breakthrough therapy, as a universal antidote for patients treated with oral and injectable Factor Xa inhibitors who are experiencing a major bleeding episode or who require emergency surgery.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical